Stephen Towe, CEO of Leo Cancer Care shared these thoughts, ‘Years of development go into changing an industry, but reaching the 510(k) pending milestone is always a wonderful celebration of everything that’s been achieved over the last few years.

“This milestone marks the beginning of change for particle therapy, with the potential to take it to more patients who need it across the globe. Thanks to the relentless work of our team and partners, leading health networks are ready, and we eagerly await the FDA’s decision.”